Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Dr. Yang Discusses the Future of Lung Cancer Treatment

September 10th 2014

James CH Yang, MD, PhD, from the National Taiwan University Hospital, discusses the future of lung cancer treatment.

Dr. Abernethy Discusses Anamorelin as a Treatment Option for Patients with Cancer Anorexia-Cachexia

September 3rd 2014

Amy P. Abernethy, MD, PhD, associate professor, School of Nursing, director, Duke Center for Learning Health Care, Duke University School of Medicine, discusses anamorelin for the treatment of cancer anorexia-cachexia.

Dr. Rizvi Discusses Pembrolizumab for Non-Small Cell Lung Cancer

August 29th 2014

Naiyer A. Rizvi, MD, an associate attending physician, Memorial Sloan Kettering Cancer Center, discusses pembrolizumab (MK-3475) for the treatment of non-small cell lung cancer (NSCLC).

Dr. Arkenau Discusses AZD4547 and FGFR Amplification in Advanced Solid Tumors

August 28th 2014

Hendrik-Tobias Arkenau, MD, PhD, medical director, Sarah Canon Research Institute, discusses an exploratory analysis of AZD4547 in patients with advanced tumors.

Not Yet Ready for Prime Time: Lessons Learned From a Failed Molecular Marker-Based Lung Cancer Trial

August 27th 2014

Scarcely a week goes by without a report in the peer-reviewed medical literature suggesting that a novel somatic genomic alteration or a specific normal polymorphism is potentially relevant to achieving a desirable clinical outcome within cancer medicine.

Pharma Collaborations Abound Across Oncology

August 21st 2014

A number of large pharmaceutical companies have forged clinical trial collaborations focused on the investigation of novel combinations and companion diagnostics across multiple cancer indications.

Dr. Herbst Discusses New Immunotherapy Agents for Lung Cancer

August 20th 2014

Roy S. Herbst, MD, PhD, a professor of medicine at the Yale Cancer Center and chief of medical oncology at Smilow Cancer Hospital at Yale-New Haven in Connecticut, discusses new immunotherapy agents showing potential as treatment options for patients with lung cancer.

Dr. Wakelee on Continued Maintenance in Lung Cancer

August 15th 2014

Heather Wakelee, MD, associate professor, Stanford University School of Medicine, discusses continued maintenance therapy in lung cancer.

Dr. Allen Discusses CO-1686 as a Treatment for Lung Cancer

August 13th 2014

Andrew R. Allen, BM, BCh, MA, MRCP, PhD, Executive Vice President of Clinical and Pre-Clinical Development, Chief Medical Officer, Co-Founder, Clovis Oncology, provides an overview of CO-1686.

Dr. Jabbari on the Potential for Implantable Cardiac Devices to Malfunction Following RT

August 12th 2014

Siavash Jabbari, MD, discusses the potential for implantable cardiac devices to malfunction following radiation therapy.

Eribulin Does Not Improve OS in Advanced NSCLC

August 11th 2014

A preliminary analysis has shown that eribulin mesylate failed to meet its primary endpoint of improving overall survival in pre-treated patients with advanced non-small cell lung cancer

Dr. Gandara Discusses Third-Generation EGFR TKIs

August 11th 2014

David R. Gandara, MD, Professor of Medicine, Division of Hematology and Oncology, Director, Thoracic Oncology Program, Associate Director, Clinical Research, UC Davis Comprehensive Cancer Center, discusses examining third-generation EGFR TKIs in lung cancer.

Dr. Cheng Discusses RICTOR Amplification in Lung Cancer

August 8th 2014

Haiying Cheng, MD, medical oncologist, Montefiore Einstein Center for Cancer Care, assistant professor, Department of Medicine (Oncology), Albert Einstein College of Medicine, discuses RICTOR amplification in patients with lung cancer.

Attacking Acquired Mutations: Researchers Aim to Make Molecularly Targeted Cancer Therapies "Smarter"

August 8th 2014

Hailed as "new ammunition in the war against cancer" and featured in TIME magazine at the turn of the new millennium, molecularly targeted therapies have gone on to revolutionize cancer treatment. Clinical responses, however, are all too often short-lived as cancer cells become resistant.

Clinical Trial Roster Shows Breadth of Ongoing Research

August 7th 2014

At Memorial Sloan Kettering, we offer a variety of clinical trials for patients with mesothelioma at all stages of their disease.

Ceritinib Demonstrates Durable Response in ALK-Positive Lung Cancer

August 7th 2014

The second-generation oral ALK inhibitor ceritinib (Zykadia; LDK378) demonstrated rapid and durable responses in patients with ALK-positive, metastatic, non–small cell lung cancer (NSCLC)-regardless of whether they had been previously treated with crizotinib-achieving overall response rates of 60% or more in each subgroup of patients who had received zero to three prior therapies for their advanced lung cancer.

Dr. Janjigian Discusses Afatinib and Cetuximab for Patients With EGFR-Mutant Lung Cancer

August 4th 2014

Yelena Y. Janjigian, MD, assistant attending physician, Memorial Sloan Kettering Cancer Center, discusses results of an early-phase study looking at afatinib and cetuximab for patients with EGFR-mutant lung cancer.

Crizotinib Established as First-Line Therapy for ALK-Positive NSCLC

August 4th 2014

As a first-line treatment, crizotinib (Xalkori) improved progression-free survival (PFS) and objective response rate (ORR) compared with standard chemotherapy in patients with advanced ALK-positive non–small cell lung cancer (NSCLC).

Next-Generation ALK Inhibitors Effective in Patients With Brain Metastases

August 2nd 2014

New generations of potent ALK inhibitors have been designed with extensive CNS activity and the ability to overcome acquired resistance mutations.

Dr. Vokes Discusses PARP Inhibitors in Lung Cancer

August 2nd 2014

Everett E. Vokes, MD, Giant of Cancer Care: Lung Cancer, John E. Ultmann Professor Chair, Department of Medicine, Physician-in-Chief, University of Chicago Medicine and Biological Sciences, discusses PARP inhibitors as treatments for patients with lung cancer.

NEXT PAGE
PREVIOUS PAGE